Endothelin receptor antagonists target EDNRB and modulate the progression of idiopathic pulmonary fibrosis via anoikis-related genes [PDF]
Frontiers in MedicineIdiopathic pulmonary fibrosis (IPF) progression involves dysregulation of anoikis-related mechanisms, though the precise molecular drivers remain unclear.
Pengfei Ning +4 more
doaj +2 more sources
Clinicians' preferences for managing aneurysmal subarachnoid hemorrhage using endothelin receptor antagonists [PDF]
Frontiers in Neurology, 2023 BackgroundThe endothelin receptor antagonist (ERA) clazosentan is being investigated for the medical prevention of cerebral vasospasm and associated complications, such as delayed cerebral ischemia (DCI), after aneurysmal subarachnoid hemorrhage (aSAH ...
Sebastian Heidenreich +3 more
doaj +2 more sources
PLoS ONE, 2014 Background Inhibition of the transporter-mediated hepatobiliary elimination of bile salts is a putative mechanism for liver toxicity observed with some endothelin receptor antagonists (ERAs). Methods Sandwich-cultured human hepatocytes were used to study
E. Lepist +7 more
semanticscholar +3 more sources
The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. [PDF]
Arch Immunol Ther Exp (Warsz), 2015 Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor, mainly secreted by endothelial cells. It acts through two types of receptors: ETA and ETB.
Kowalczyk A +4 more
europepmc +3 more sources
The gastrointestinal endothelin system: receptors, cellular actions, and involvement in gastrointestinal disorders [PDF]
Gastroenterology ReviewThe gastrointestinal endothelin system regulates vital processes including motility, secretion, sensation, and inflammation. Endothelin-1 acts via endothelin A and B receptors expressed on diverse intestinal cells.
Arjun Singh, Rajvir Singh
doaj +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundEvidence of the clinical safety of endothelin receptor antagonists (ERAs) is limited and derived mainly from individual trials; therefore, we conducted a meta‐analysis.
Anhua Wei +6 more
doaj +2 more sources
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs) [PDF]
Frontiers in PharmacologyThe emergence of targeted anti-tumor drugs has significantly prolonged the lifespan and improved the prognosis of cancer patients. Among these drugs, vascular endothelial growth factor (VEGF) inhibitors, particularly novel small molecule tyrosine kinase ...
Qingjian He +11 more
doaj +2 more sources
Iontophoresis of endothelin receptor antagonists in rats and men. [PDF]
PLoS ONE, 2012 The treatment of scleroderma-related digital ulcers is challenging. The oral endothelin receptor antagonist (ERA) bosentan has been approved but it may induce liver toxicity.
Matthieu Roustit +9 more
doaj +2 more sources
Clinical and hemodynamic effect of endothelin receptor antagonists in eisenmenger syndrome
Annals of Pediatric Cardiology, 2020 Introduction: Endothelin receptor antagonists (ERAs) are widely accepted as a specific treatment for pulmonary arterial hypertension. Unfortunately, consensus and recommendations are lacking for the treatment of patients who suffer from pulmonary ...
Emir Yonas +6 more
doaj +2 more sources
Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs [PDF]
Circulation, 2000 Abstract—The 21-amino acid peptide endothelin-1 (ET-1) is the predominant isoform of the endothelin peptide family, which includes ET-2, ET-3, and ET-4. It exerts various biological effects, including vasoconstriction and the stimulation of cell proliferation in tissues both within and outside of the cardiovascular system.
T. Lüscher, M. Barton
semanticscholar +3 more sources